Biorbyt

 

Biorbyt is a UK-based supplier specializing in life science reagents. They offer a wide range of products, including antibodies, ELISA kits, small molecules, and proteins. Researchers can choose from thousands of research antibodies and reagents for various applications. Biorbyt collaborates with top scientists and scholars to develop high-quality products, covering areas such as immunology, cell biology, molecular biology, and proteinomics. Their comprehensive offerings include immune assays, protein mass spectrometry, cell culture, custom antibody services, animal model establishment, and biochemical reagents. 

Biorbyt provides valuable reagents and services for biological research. With a wide selection of antibodies, assay kits, small molecules, and proteins, Biorbyt supports scientists in their experiments. They have established stable partnerships with renowned universities, research institutes, pharmaceutical companies, biotech firms, and hospitals worldwide. Biorbyt’s commitment to high-quality products and professional technical services spans immunology, cell biology, molecular biology, proteinomics, and more.

 

Learn more :

 

 

 

 

         

Antibodies - Chicken Ig Why ?

 

 

   

Cancer Pathways

Apoptosis Signaling

 

 

Fix & Perm Cell Fixation

and Permeabilization

 

 

   

         

Immunology Pathways

 

 

Products for advancing

discoveries

 

Working in larger model

animal species

 
 

Watch the videos: 

     

 

       
         

Recombinant Antibodies

 

 

 

 

Cancer Biomarkers

 

 
 
 
SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates

SARS-CoV-2 - Ruxolitinib - Therapeutic Candidates


Ruxolitinib, whose commercial name is Jakavi, is a tyrosine kinase inhibitor and more specifically Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are JAK-targeting tyrosine kinases.  Ruxolitinib is used for the treatment of certain myeloproliferative syndromes such as myelofibrosis. It is also used for the treatment of Vaquez disease (essential polyglobulia or polycythemia vera or rubra), characterized by polyglobulia and an increase in total blood cell volume.
The Novartis group, which markets Jakavi, began studying the effects of this drug on Covid-19 caused by SARS-CoV-2. The purpose of this clinical study is to determine whether ruxolitinib could mitigate the potential complications of Covid-19 and involves patients with Covid-19-related cytokine shock. This Phase III clinical study is based on the fact that the JAK-STAT pathway is fundamental to many biological processes related to immunity and inflammation, including the mobilization of a cytokine response.

Search result : 85 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 2
  • Biochemicals 83
  • Inhibitor/Antagonist/Agonist 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
orb1307364-5mg
 5mg 
orb1307364-200mg
 200mg 
orb1223575-50mg
 50mg 
orb1223575-200mg
 200mg 
orb1307364-50mg
 50mg 
orb1307364-100mg
 100mg 
orb1223575-100mg
 100mg 
orb1223575-10mg
 10mg 
orb1223575-25mg
 25mg 
orb1223575-5mg
 5mg 
orb1307364-25mg
 25mg 
orb1307364-10mg
 10mg 
orb340673-25mg
 25mg 
orb340673-5mg
 5mg 
orb1713634-5mg
 5mg 
orb1713635-25mg
 25mg 
orb1688050-100mg
 100mg 
orb1183493-50mg
 50mg 
orb1688050-5mg
 5mg 
orb1227517-25mg
 25mg